IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA is a premier journal published by W B SAUNDERS CO-ELSEVIER INC, focusing on the dynamic fields of immunology and allergy. With an ISSN of 0889-8561 and an E-ISSN of 1557-8607, this journal has consistently ranked in the Q2 category in both Immunology and Immunology and Allergy as per 2023 metrics, underscoring its critical role in academia. It provides cutting-edge research, comprehensive reviews, and practical insights that cater to the needs of researchers, clinicians, and students alike. Though the journal is not open access, it remains an essential resource for those involved in advancing knowledge and clinical practice in allergy and immunology. With its converged years stretching from 1987 to 2024, the journal serves as a rich repository of scientific advancements, fostering progress in diagnosis, treatment, and prevention of allergic diseases and immune disorders. Positioned within the United States and based in Philadelphia, it plays a vital role in promoting scholarly communication within these impactful fields.

ALLERGY is a leading international journal published by WILEY, dedicated to advancing the understanding of allergic diseases and immunology. With an ISSN of 0105-4538 and an E-ISSN of 1398-9995, this esteemed journal has been at the forefront of the field since its inception in 1948 and continues to publish high-quality research up until 2024. Positioned in the Q1 category for both Immunology and Allergy, ALLERGY ranks impressively within the top percentiles of its categories, underscoring its significant impact, as reflected in its Scopus rankings (#11 out of 233 in Immunology and Allergy, and #14 out of 236 in Immunology and Microbiology). Researchers and practitioners accessing this journal can expect a rigorous selection of peer-reviewed articles that address current challenges, innovative therapies, and advancements in the immunological sciences. Although it is not an open-access journal, ALLERGY remains vital for academics, healthcare professionals, and students alike, fostering a deeper understanding of the mechanisms and treatments associated with allergies.

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY is an esteemed publication dedicated to the fields of Immunology and Allergy, published by ESMON PUBLICIDAD S A in collaboration with the Department of Allergy and Clinical Immunology at the University Clinical Navarra, Spain. With its rich history spanning over three decades since its inception in 1991, this journal has gained prominence in the scientific community, holding a commendable Q2 quartile in Allergy and a Q3 quartile in Immunology. Ranked within the top tiers of its categories according to Scopus, it stands at Rank #80/233 in Immunology and Allergy, and Rank #96/236 in Immunology and Microbiology, indicating its influential role in disseminating cutting-edge research and clinical insights. Though primarily print-focused, the journal strives to bridge gaps in knowledge and contribute to the ongoing dialogue among researchers, professionals, and students in the immunological sciences. The JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY is essential for anyone committed to advancing the understanding of allergic and immunological conditions.

World Allergy Organization Journal is a premier open-access publication dedicated to advancing the understanding and treatment of allergic diseases and related conditions. Published by ELSEVIER, this journal boasts a commendable impact factor and ranks in the second quartile for both Immunology and Allergy, as well as the first quartile in Pulmonary and Respiratory Medicine. Since its inception as an open-access journal in 2008, it has consistently aimed to provide a credible platform for researchers, clinicians, and students to disseminate original research, reviews, and clinical studies. With its emphasis on high-quality scholarship and practical applications, the World Allergy Organization Journal plays a crucial role in bridging theoretical knowledge with clinical practice, making significant contributions to the fields of immunology, allergy, and respiratory medicine. The journal is particularly notable for its accessibility to a global audience, exemplified by its open-access model since 2008, promoting a wider exchange of ideas and innovations across borders.

Asia Pacific Allergy, published by Lippincott Williams & Wilkins, is a prominent academic journal dedicated to advancing research and clinical practice in the fields of dermatology, immunology, and allergy. With its ISSN 2233-8276 and E-ISSN 2233-8268, the journal provides a platform for innovative studies and reviews that cater to an international audience of researchers, healthcare professionals, and students involved in allergy and related disorders. Although it does not currently offer open access to its publications, the journal's robust output from 2015 to 2017 and its ongoing contribution to the literature from 2021 to 2024 showcase the evolving landscape of allergy research in the Asia Pacific region. Recognized in the 2023 Journal Citation Reports, it holds a Q2 ranking in Dermatology and a Q3 ranking in Immunology and Allergy, while its Scopus ranks further emphasize its significance within these domains, positioning it among the top journals in the field. As a source of cutting-edge research, Asia Pacific Allergy plays a vital role in fostering collaboration and knowledge dissemination, ultimately assisting in the betterment of patient care and treatment strategies across the region.

The Journal of Allergy and Clinical Immunology-In Practice, published by ELSEVIER, stands as a leading platform in the field of allergy and immunology, specifically tailored for practitioners and researchers. With an impressive 2023 Q1 ranking in both the Immunology and Allergy categories, this journal demonstrates a significant impact within the academic community, evidenced by its Scopus rank #41 out of 233 and an impressive percentile rank of 82. The journal focuses on providing advanced studies, clinical findings, and innovative treatment methodologies that address current challenges in allergy and immunology, making it a vital resource for professionals in these fields. With a comprehensive coverage of relevant topics from 2013 to 2024, the journal continues to evolve alongside emerging trends and developments in clinical practice, fostering an environment conducive to scholarly research and application. Although it currently does not offer open access, authors and readers can access a wealth of information and contribute to ongoing dialogues through its robust publication platform.

Welcome to the Allergo Journal, a pivotal publication in the field of Immunology and Allergy, housed under the esteemed SPRINGER HEIDELBERG publishing house. With an ISSN of 0941-8849 and E-ISSN 2195-6405, the journal has been serving the scientific community since its inception in 1994. Although its Scopus coverage was discontinued in 2017, the journal remains significant, ranked #135 out of 186 in its category and positioned in the 27th percentile, reflecting its contributions to vital research in allergy and immunological disorders. While the journal is not an open access publication, it continues to provide a platform for rigorous academic discourse and advances in the study of allergens and immune response. The Allergo Journal stands as a crucial resource for researchers, professionals, and students dedicated to deepening their understanding of allergies and immunology, fostering advancements in therapy and comprehensive patient care.

The Revue Francaise d'Allergologie, an esteemed publication in the field of Immunology and Allergy, is published by ELSEVIER MASSON, CORP OFF in France. This journal plays a pivotal role in disseminating significant findings and advancements in allergy research and immunotherapy, reflecting the latest trends and challenges in these rapidly evolving areas. As part of its commitment to scholarly rigor, the journal encompasses a wide range of topics pertinent to allergology, aiming to bridge the gap between clinical practice and academic research. Although currently not listed as open access, it provides critical insights essential for researchers, professionals, and students alike, ensuring the advancement of knowledge and therapeutic strategies in allergy and immunology. With its impact factor and positioning in the Q4 category, it serves as a valuable resource, aiding in the education and development of future leaders in the field. The Revue Francaise d'Allergologie continues to be a vital platform for the exchange of innovative ideas and findings from 2009 to the present.

Gastrointestinal Disorders is a prominent open-access journal published by MDPI, based in Switzerland, that focuses on the latest research and innovations in the fields of gastroenterology, hepatology, and immunology. Since its inception in 2019, the journal has provided a vital platform for researchers and professionals to disseminate their findings, engaging with a global audience keen on advancing knowledge in gastrointestinal health. With a dedicated commitment to high-quality, peer-reviewed articles, Gastrointestinal Disorders has gained recognition in 2023, achieving Q3 status in gastroenterology and notable rankings in several other categories, including a respectable position in the quartiles for hepatology, immunology, and oncology. Despite its recent establishment, the journal has quickly become a valuable resource, facilitating open access to critical insights in the study of gastrointestinal diseases and their management, ensuring that emerging research is readily available to inform clinical practice and educate future professionals.

Current Allergy & Clinical Immunology is a vital peer-reviewed journal published by the Allergy Society of South Africa, focused on advancing the field of immunology and allergy medicine. With an ISSN of 1609-3607, this journal offers crucial insights and research findings pertinent to the understanding and treatment of allergic conditions. Operating from South Africa, it features contributions from a diverse range of authors and professionals in the field. Published from 2008 to 2024, the journal plays an essential role in disseminating current knowledge, even as it holds a Q4 ranking in Immunology and Allergy and is positioned at the 4th percentile based on Scopus rankings. While not open access, it remains an important resource for researchers, practitioners, and students looking to stay informed on emerging trends and breakthroughs in allergy and clinical immunology.